JP2022541152A - 多形態眼球製剤および治療法 - Google Patents

多形態眼球製剤および治療法 Download PDF

Info

Publication number
JP2022541152A
JP2022541152A JP2022501111A JP2022501111A JP2022541152A JP 2022541152 A JP2022541152 A JP 2022541152A JP 2022501111 A JP2022501111 A JP 2022501111A JP 2022501111 A JP2022501111 A JP 2022501111A JP 2022541152 A JP2022541152 A JP 2022541152A
Authority
JP
Japan
Prior art keywords
copper
composition
ophthalmic
eye
ophthalmic composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022501111A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022541152A5 (https=
Inventor
マイケル バール、ランドン
ケイ． アンバーティ、バラムラリ
エー． モロキア、サラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation Inc
Original Assignee
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc
Publication of JP2022541152A publication Critical patent/JP2022541152A/ja
Publication of JP2022541152A5 publication Critical patent/JP2022541152A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2022501111A 2019-07-11 2020-07-13 多形態眼球製剤および治療法 Pending JP2022541152A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962873121P 2019-07-11 2019-07-11
US62/873,121 2019-07-11
PCT/US2020/041837 WO2021007578A1 (en) 2019-07-11 2020-07-13 Multi-agent ocular formulations and treatment methods

Publications (2)

Publication Number Publication Date
JP2022541152A true JP2022541152A (ja) 2022-09-22
JP2022541152A5 JP2022541152A5 (https=) 2023-07-21

Family

ID=74115334

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022501111A Pending JP2022541152A (ja) 2019-07-11 2020-07-13 多形態眼球製剤および治療法

Country Status (8)

Country Link
US (1) US20220288114A1 (https=)
EP (1) EP3996644A4 (https=)
JP (1) JP2022541152A (https=)
KR (1) KR20220125210A (https=)
CN (1) CN114364355A (https=)
AU (2) AU2020311441B2 (https=)
CA (1) CA3146848A1 (https=)
WO (1) WO2021007578A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019205774B2 (en) * 2018-01-05 2025-01-02 University Of Utah Research Foundation Treatment of myopic progression
TW202245810A (zh) * 2021-02-01 2022-12-01 美商艾維娜傳送系統公司 散光之治療
CN114225016B (zh) * 2021-12-02 2024-07-09 北京大学第一医院 一种用于抑制近视及圆锥角膜进展的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017155580A1 (en) * 2016-03-08 2017-09-14 University Of Utah Research Foundation Cross-linking agents and associated methods
WO2019136358A1 (en) * 2018-01-05 2019-07-11 Iveena Delivery Systems, Inc. Treatment of myopic progression

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04502012A (ja) * 1989-09-27 1992-04-09 モスコフスキ　ナウチノ―イススレドバテルスキ　インスティテュト　グラツィニフ　ボレツネイ　イメニ　ゲルムゴルツァ 進行性近視の治療用組成物
AU7488898A (en) * 1997-05-16 1998-12-08 Corrective Vision, Inc. Improved contact lens
EP1397132A4 (en) * 2001-05-25 2006-12-13 Valley Forge Pharmaceuticals I OPHTHALMIC PIRENZEPINE GEL
US20060134226A1 (en) * 2004-11-16 2006-06-22 Todd Leonard Compositions useful to treat ocular neovascular diseases and macular degeneration
WO2012161655A1 (en) * 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine
US9421199B2 (en) * 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US10010502B2 (en) * 2015-05-19 2018-07-03 Amorphex Therapeutics Llc Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
US20200345542A1 (en) * 2017-11-21 2020-11-05 Sydnexis, Inc. Ophthalmic composition and delivery device thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017155580A1 (en) * 2016-03-08 2017-09-14 University Of Utah Research Foundation Cross-linking agents and associated methods
WO2019136358A1 (en) * 2018-01-05 2019-07-11 Iveena Delivery Systems, Inc. Treatment of myopic progression

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"角膜強化法について", 品川近視クリニック 梅田院のブログ, JPN6025017758, 2012, ISSN: 0005591790 *
ARVO ANNUAL MEETING ABSTRACT, JPN6025017757, May 2019 (2019-05-01), pages 5896, ISSN: 0005591792 *
EYE, vol. 25, JPN6025017760, 2011, pages 1083 - 1089, ISSN: 0005591789 *
IOL&RS, vol. 25巻4号, JPN6025017759, 2012, pages 488 - 492, ISSN: 0005591791 *
あたらしい眼科, vol. 33(10), JPN6024031031, 2016, pages 1443 - 1448, ISSN: 0005722284 *
あたらしい眼科, vol. 33(10), JPN6024031032, 2016, pages 1419 - 1426, ISSN: 0005722285 *

Also Published As

Publication number Publication date
CA3146848A1 (en) 2021-01-14
CN114364355A (zh) 2022-04-15
AU2020311441B2 (en) 2025-12-04
US20220288114A1 (en) 2022-09-15
AU2026201640A1 (en) 2026-03-26
WO2021007578A1 (en) 2021-01-14
EP3996644A1 (en) 2022-05-18
KR20220125210A (ko) 2022-09-14
AU2020311441A1 (en) 2022-02-03
EP3996644A4 (en) 2023-07-26

Similar Documents

Publication Publication Date Title
AU2023202236B2 (en) Cross-linking agents and associated methods
US12544400B2 (en) Treatment of myopic progression
AU2026201640A1 (en) Multi-agent ocular formulations and treatment methods
US20240122974A1 (en) Treatment of myopia
HK40107891A (en) Cross-linking agents and associated methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230712

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240806

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250103

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250513

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250809

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260227